半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展

doi:10.16138/j.1673-6087.2022.01.020

摘要/Abstract

中图分类号:

朱秋艳, 薛岑. 半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展[J]. 内科理论与实践, 2022, 17(01): 102-106.

参考文献 45

[1]	李正欢, 张晓云, 陈杨, 等. 2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读(一)——稳定期药物管理[J]. 中国全科医学, 2021, 24(8): 923-929. doi: 10.12114/j.issn.1007-9572.2021.00.155
[2]	Telo S, Kuluöztürk M, Deveci F, et al. Serum cystatin C levels in COPD: potential diagnostic value and relation between respiratory functions[J]. J Med Biochem, 2018, 37(4): 434-440. doi: 10.1515/jomb-2017-0063 URL
[3]	Chai L, Feng W, Zhai C, et al. The association between cystatin C and COPD: a meta-analysis and systematic review[J] .BMC Pulm Med, 2020, 20(1): 182. doi: 10.1186/s12890-020-01208-5 URL
[4]	Formiga MF, Vital I, Urdaneta G, et al. Higher serum levels of systemic inflammatory markers are linked to greater inspiratory muscle dysfunction in COPD[J]. Clin Respir J, 2019, 13(4): 247-255. doi: 10.1111/crj.13006 pmid: 30773817
[5]	赖雯, 吴东, 黄丹, 等. 血清胱抑素C对慢性阻塞性肺疾病急性加重风险的诊断价值[J]. 广东医科大学学报, 2020, 38(3):283-286.
[6]	Amado CA, García-Unzueta MT, Lavin BA, et al. The ratio serum creatinine/serum cystatin C (a surrogate marker of muscle mass) as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients[J]. Respiration, 2019, 97(4): 302-309. doi: 10.1159/000494296 URL
[7]	Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease[J]. Clin Nutr, 2021, 40(3): 1274-1280. doi: 10.1016/j.clnu.2020.08.010 URL
[8]	Hu G, Wu Y, Zhou Y, et al. Cystatin C as a predictor of in-hospital mortality after exacerbation of COPD[J]. Respir Care, 2016, 61(7): 950-957. doi: 10.4187/respcare.04034 URL
[9]	崔顺顺, 杨瑞青. 慢性阻塞性肺疾病合并肺动脉高压患者血清Cys-C水平变化及意义[J]. 临床肺科杂志, 2018, 23(1): 32-34.
[10]	陈玉群, 肖叶, 胡大碧, 等. 血清同型半胱氨酸、胱抑素C水平对COPD合并呼吸衰竭患者预后的影响[J]. 中国煤炭工业医学杂志, 2020, 23(3): 293-298.
[11]	邓正旭, 陈红, 文艳梅, 等. COPD患者血清胱抑素C、NT-proBNP、尿酸水平与病情严重程度及心脏受累的相关性分析[J]. 标记免疫分析与临床, 2020, 27(3): 471-475.
[12]	Yoshizawa T, Okada K, Furuichi S, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels[J]. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1283-1289.
[13]	Chen D, Cao C, Jiang L, et al. Serum cystatin C: a potential predictor for hospital-acquired acute kidney injury in patients with acute exacerbation of COPD[J]. Chron Respir Dis, 2020, 17(11): 1479973120940677.
[14]	Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea[J]. JAMA, 2020, 323(14): 1389-1400. doi: 10.1001/jama.2020.3514 pmid: 32286648
[15]	Voulgaris A, Archontogeorgis K, Nena E, et al. Serum levels of NGAL and cystatin C as markers of early kidney dysfunction in patients with obstructive sleep apnea syndrome[J]. Sleep Breath, 2019, 23(1): 161-169. doi: 10.1007/s11325-018-1677-8 URL
[16]	Chuang LP, Lin SW, Lee LA, et al. Elevated serum markers of acute kidney injury in patients with obstructive sleep apnea[J]. J Clin Sleep Med, 2019, 15(2): 207-213. doi: 10.5664/jcsm.7618 pmid: 30736871
[17]	Chen DD, Huang JF, Huang SP, et al. Association of serum adiponectin level with cystatin C in male patients with obstructive sleep apnea syndrome[J]. Sleep Breath, 2020, 24(3): 953-960. doi: 10.1007/s11325-019-01927-y URL
[18]	Liu T, Zhan Y, Wang Y, et al. Obstructive sleep apnea syndrome and risk of renal impairment: a systematic review and meta-analysis with trial sequential analysis[J]. Sleep Breath, 2021, 25(1): 17-27. doi: 10.1007/s11325-020-02090-5 URL
[19]	Nowiński A, Czyzak-Gradkowska A, Jonczak L, et al. Glomerular filtration rate in patients with obstructive sleep apnea: the influence of cystatin-C-based estimations and comorbidity[J]. J Thorac Dis, 2020, 12(3): 175-183. doi: 10.21037/jtd.2020.02.11 pmid: 32274082
[20]	Zhang XB, Jiang XT, Lin QC, et al. Effect of continuous positive airway pressure on serum cystatin C among obstructive sleep apnea syndrome patients[J]. Int Urol Nephrol, 2014, 46(10): 1997-2002. doi: 10.1007/s11255-014-0779-x URL
[21]	Menou A, Duitman J, Crestani B. The impaired proteases and anti-proteases balance in idiopathic pulmonary fibrosis[J] .Matrix Biol, 2018, 68-69: 382-403. doi: S0945-053X(17)30471-7 pmid: 29518524
[22]	Kasabova M, Joulin-Giet A, Lecaille F, et al. Regulation of TGF-β1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystatin C[J]. J Biol Chem, 2014, 289(23): 16239-16251. doi: 10.1074/jbc.M113.542407 pmid: 24790080
[23]	Kasabova M, Villeret B, Gombault A, et al. Discordance in cathepsin B and cystatin C expressions in bronchoalveolar fluids between murine bleomycin-induced fibrosis and human idiopathic fibrosis[J]. Respir Res, 2016, 17(1): 118. doi: 10.1186/s12931-016-0432-6 URL
[24]	Zhang D, Huang C, Yang C, et al. Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts[J]. Respir Res, 2011, 12(1): 154. doi: 10.1186/1465-9921-12-154 URL
[25]	Saidi A, Kasabova M, Vanderlynden L, et al. Curcumin inhibits the TGF-β1-dependent differentiation of lung fibroblasts via PPARγ-driven upregulation of cathepsins B and L[J]. Sci Rep, 2019, 9(1): 491. doi: 10.1038/s41598-018-36858-3 URL
[26]	Kim YI, Shin HW, Chun YS, et al. Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis[J]. Cell Death Dis, 2018, 9(5): 506. doi: 10.1038/s41419-018-0530-0 URL
[27]	Lee YT, Chen SC, Shyu LY, et al. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia[J]. Clin Chim Acta, 2012, 413(5-6): 630-635. doi: 10.1016/j.cca.2011.12.010 URL
[28]	卞韬, 谭明旗. 胱抑素C评估社区获得性肺炎严重程度的临床研究[J]. 中国基层医药, 2019, 26(13): 1566-1569.
[29]	杨婷, 曾子鉴, 申永春, 等. 胱抑素C评估社区获得性肺炎患者严重程度及预测住院期间死亡概率的临床研究[J]. 华西医学, 2018, 33(1): 28-31.
[30]	芦烨, 陈愉, 赵立. 多种生物标志物与社区获得性肺炎严重程度的相关性分析[J]. 国际呼吸杂志, 2020, 40(19): 1486-1490.
[31]	张雨婷, 韩旭. 胱抑素C预测重症肺炎的价值分析[J]. 中国基层医药, 2019, 26(17):2075-2078.
[32]	候茜, 宁沛雯. 血清IL-18与胱抑素C在社区获得性肺炎伴发急性肾损伤中的诊断价值[J]. 检验医学与临床, 2017, 11(14): 76-77.
[33]	Abdelaal NA, Shalaby SA, Khashana AK, et al. Serum cystatin C as an earlier predictor of acute kidney injury than serum creatinine in preterm neonates with respiratory distress syndrome[J]. Scand J Clin Lab Invest, 2017, 28(5): 1003-1014.
[34]	El-Gammacy TM, Shinkar DM, Mohamed NR, et al. Serum cystatin C as an early predictor of acute kidney injury in preterm neonates with respiratory distress syndrome[J]. Scand J Clin Lab Invest, 2018, 78(5): 352-357. doi: 10.1080/00365513.2018.1472803 URL
[35]	Hendrickson CM, Kwong YD, Belzer AG, et al. Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy[J]. Crit Care, 2020, 24(1): 416. doi: 10.1186/s13054-020-03111-1 URL
[36]	Kostrubiec M, Łabyk A, Pedowska-Włoszek J, et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism[J]. Heart, 2012, 98(16): 1221-1228. doi: 10.1136/heartjnl-2012-301884 pmid: 22705926
[37]	Tutar N, Kemik NA, Yılmaz I, et al. Is serum cystatin C a predictor of acute pulmonary thromboembolism in patients with normal renal function?[J]. Clin Appl Thromb Hemost, 2015, 21(6): 533-538. doi: 10.1177/1076029613512416 URL
[38]	Leto G, Crescimanno M, Flandina C. On the role of cystatin C in cancer progression[J]. Life Sci, 2018, 202: 152-160. doi: 10.1016/j.lfs.2018.04.013 URL
[39]	Breznik B, Mitrović A, T Lah T, et al. Cystatins in cancer progression: more than just cathepsin inhibitors[J]. Biochimie, 2019, 166: 233-250. doi: 10.1016/j.biochi.2019.05.002 URL
[40]	Naumnik W, Niklińska W, Ossolińska M, et al. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy[J]. Folia Histochem Cytobiol, 2009, 47(2): 207-213.
[41]	Ohara G, Miyazaki K, Kurishima K, et al. Serum levels of cystatin C in elderly lung cancer patients[J]. Oncol Lett, 2012, 3(2): 303-306. pmid: 22740900
[42]	张学德, 侯彦丽, 牛泽群, 等. 检测肺癌患者血清Cathepsin X及Cystatin C的临床意义[J]. 中国肺癌杂志, 2013, 16(8): 411-416.
[43]	杨燕君, 董跃华, 王大伟, 等. 非小细胞肺癌患者血清胱抑素C及同型半胱氨酸的表达水平及其与淋巴结转移的相关性[J]. 中国老年学杂志, 2019, 39(17): 4189-4190.
[44]	Wang H, Shan D, Dong Y, et al. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer[J]. Oncol Lett, 2021, 21(1): 73. doi: 10.3892/ol.2020.12334 URL
[45]	熊胜春, 吴静, 井洪家, 等. 胱抑素C及β2-微球蛋白中性粒细胞明胶酶相关脂质运载蛋白联合检测在肺癌患者化疗相关肾损伤早期检测中的作用[J]. 中华老年医学杂志, 2018, 37(10): 1107-1110.

半胱氨酸蛋白酶抑制剂C在呼吸系统疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李士杰　姜爱莉　刘宇　王召旭　韩倩倩. 巨噬细胞介导的炎症反应在材料生物相容性评价中的意义[J]. 组织工程与重建外科杂志, 2022, 18(5): 436-.
[2]	刘锐锋, 盛倩倩, 张悦, 赵慧强. 冠状动脉扩张患者淋巴细胞和单核细胞亚型分析[J]. 内科理论与实践, 2022, 17(05): 373-378.
[3]	闫晓红, 薄建萍. 呼出气一氧化氮在下气道慢性炎症疾病中的评估价值[J]. 内科理论与实践, 2022, 17(05): 418-422.
[4]	杜燕然, 焦景, 任芸芸, 周建桥. 超声影像组学技术在评估胎肺成熟度中的应用[J]. 诊断学理论与实践, 2022, 21(03): 326-330.
[5]	刘萍, 肖园, 王歆琼, 陆亭伟, 赵雪松, 杨媛艳. Wiskott-Aldrich综合征合并克罗恩病一例并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 349-354.
[6]	戴生明. 银屑病关节炎的诊治现状与挑战[J]. 内科理论与实践, 2022, 17(03): 186-189.
[7]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[8]	王毅, 李红鹏, 张力月, 李庆云. 瘦素与重度哮喘的关联及机制研究进展[J]. 内科理论与实践, 2022, 17(01): 88-91.
[9]	雷晓旭王春赵曦. 炎症微环境作用下ＢＭＰｓ－ＥＲＫ５信号通路对牙周膜干细胞成骨分化的影响 #br#[J]. 组织工程与重建外科杂志, 2021, 17(1): 30-.
[10]	宋娟, 邢寅, 黄慧, 陆帅, 秦利. 上海市崇明地区中老年人群血白细胞计数与血尿酸水平相关性研究[J]. 内科理论与实践, 2021, 16(06): 413-417.
[11]	查晴, 于晨溪, 刘亚, 杨玲, 叶佳雯, 刘艳. miR-16在冠状动脉粥样硬化斑块进展中的作用及初步机制研究[J]. 诊断学理论与实践, 2021, 20(01): 82-87.
[12]	刘冰滢, 王文波, 黄佳, 高振, 武晓莉, 刘伟. 积雪草酸葡糖胺盐凝胶通过调节巨噬细胞迁移和极化促进创面愈合及表皮再生[J]. 组织工程与重建外科杂志, 2020, 16(2): 112-118.
[13]	程雨龙, 杨松林, 邓辰亮, 郑江红. 桃叶珊瑚苷抑制机械张力诱导增生性瘢痕的机制研究[J]. 组织工程与重建外科杂志, 2020, 16(2): 119-122.
[14]	康建强, 董杨阳, 杨玲, 宋珍, 范嘉盈. 下呼吸道流感嗜血杆菌定植对哮喘小鼠气道炎症的影响及信号通路的研究[J]. 诊断学理论与实践, 2020, 19(1): 44-49.
[15]	郭恩伟, 任大力, 章冰玉, 杨峰, 姚峪岚, 贾凌, 余琳, 冯刚. 创伤病人血清游离线粒体含量变化及其临床意义[J]. 外科理论与实践, 2020, 25(04): 315-321.